Capricor Therapeutics (NASDAQ:CAPR) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research note published on Tuesday, Marketbeat.com reports. HC Wainwright currently has a $60.00 price objective on the biotechnology company’s stock.

Several other equities analysts have also recently weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Capricor Therapeutics in a report on Wednesday, January 14th. UBS Group set a $50.00 target price on Capricor Therapeutics in a research note on Monday, December 15th. Oppenheimer raised their target price on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Capricor Therapeutics in a research note on Monday, December 29th. Finally, B. Riley Financial reiterated a “buy” rating and issued a $50.00 price target (up from $21.00) on shares of Capricor Therapeutics in a report on Monday, December 15th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $40.82.

Capricor Therapeutics Trading Up 9.0%

NASDAQ:CAPR opened at $33.40 on Tuesday. Capricor Therapeutics has a 1 year low of $4.30 and a 1 year high of $40.37. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of -18.56 and a beta of 0.37. The stock has a 50-day moving average price of $25.47 and a two-hundred day moving average price of $16.11.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of CAPR. GSA Capital Partners LLP bought a new stake in Capricor Therapeutics in the 3rd quarter valued at approximately $1,555,000. Geode Capital Management LLC grew its stake in shares of Capricor Therapeutics by 6.8% during the 2nd quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company’s stock worth $9,565,000 after acquiring an additional 61,701 shares in the last quarter. HBK Sorce Advisory LLC raised its holdings in shares of Capricor Therapeutics by 33.7% in the third quarter. HBK Sorce Advisory LLC now owns 170,577 shares of the biotechnology company’s stock valued at $1,141,000 after purchasing an additional 42,951 shares during the last quarter. Citizens Financial Group Inc. RI raised its holdings in shares of Capricor Therapeutics by 249.2% in the second quarter. Citizens Financial Group Inc. RI now owns 35,000 shares of the biotechnology company’s stock valued at $348,000 after purchasing an additional 24,977 shares during the last quarter. Finally, First Financial Bank Trust Division bought a new stake in shares of Capricor Therapeutics in the third quarter worth $203,000. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics News Summary

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: FDA resumed review of the Biologics License Application for Deramiocel and lifted the prior Complete Response Letter; the resubmission is classified as a Class 2 with a PDUFA target action date of August 22, 2026 — a clear regulatory catalyst toward potential approval. Article Title
• Positive Sentiment: HC Wainwright reiterated a Buy rating and set a $60 price target (implying substantial upside from current levels), which can support investor confidence and buying interest. Article Title
• Neutral Sentiment: Capricor will report Q4 and full-year 2025 results and provide a corporate update on March 12 — this is a near-term event that could add volatility depending on financials and program updates. Article Title
• Neutral Sentiment: News that the FDA CBER head (Dr. Vinay Prasad) is leaving in April introduces some regulatory leadership change risk/uncertainty for biotech review dynamics, but the direct impact on CAPR’s review timeline is unclear. Article Title
• Neutral Sentiment: Reported large short-interest “increase” items show zero shares and NaN changes — this appears to be a data anomaly and is unlikely to be a meaningful driver unless later confirmed by accurate short-interest filings.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.